Biotech startup Bugworks Research raised $18 million Series B1 round led by Lightrock India where existing investors, including 3one4 Capital with other investors The University of Tokyo Edge Capital (UTEC) Japan, Global Brain Corporation, South Africa-based Acquipharma Holdings, I.M Holdings and Featherlite Group India, Kiran Mazumdar-Shaw, CMD, Biocon also participated.
Bugworks is a drug discovery firm that seeks to discover novel pharmaceutical assets to combat antimicrobial resistance (AMR). This funding will help the company continue to develop BWC0977, a broad-spectrum anti-bacterial agent, into the clinic. Bugworks stated that it will continue to invest in its own drug discovery platforms. CARB-X, a global non-profit partnership dedicated to accelerating antibacterial research, is supporting Bugworks' top antibacterial asset BWC0977.